以岭药业与乐药集团达成合作 共拓医药健康产业新篇章

Core Insights - Yiling Pharmaceutical and Leyao Group have signed a cooperation agreement to establish a long-term, stable, and comprehensive partnership aimed at promoting high-quality development in China's pharmaceutical and health industry [1][6]. Group 1: Company Profiles - Yiling Pharmaceutical is a leading enterprise in the Chinese traditional medicine sector, focusing on technological innovation and has developed over ten patented new drugs targeting major diseases such as cardiovascular diseases, respiratory infections, tumors, and diabetes [3]. - Leyao Group, with a registered capital of $256 million, operates as a new type of "pharmaceutical + internet" enterprise, focusing on pharmaceutical distribution and optimizing supply chain efficiency through e-commerce and logistics technology [3]. Group 2: Digital Transformation - Yiling Pharmaceutical is actively embracing digitalization, having established deep partnerships with several well-known e-commerce platforms to expand its "internet + health" service model [4]. - A significant collaboration with JD Health was initiated to launch a digital marketing project aimed at promoting core products like the Ba Zi Bu Shen capsule, providing comprehensive health management solutions for aging populations [4][5]. Group 3: Strategic Cooperation - The cooperation between Yiling Pharmaceutical and Leyao Group will leverage their respective strengths in branding, research, production, technology, marketing, and distribution to enhance core competitiveness and better serve patients and consumers [6]. - A regular high-level meeting mechanism and joint working groups will be established to ensure efficient progress and execution of strategic cooperation projects, focusing on key issues such as channel management and market coverage [7]. Group 4: Industry Impact - This strategic partnership is seen as a significant step for both companies and is expected to set a new benchmark for industry collaboration, injecting new momentum into the development of China's pharmaceutical and health industry [9].